Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms

被引：2
|
作者：
Diamond, Eli L. [1 ]
Durham, Benjamin [2 ]
Dogan, Ahmet [3 ]
Yabe, Mariko [4 ]
Petrova-Drus, Kseniya [3 ]
Rampal, Raajit K. [5 ]
Ulaner, Gary [6 ]
Lacouture, Mario [7 ]
Rotemberg, Veronica [7 ]
Covey, Anne [2 ]
Brody, Lynn [8 ]
Abdel-Wahab, Omar [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Hematopathol Serv, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
[6] Hoag Family Canc Inst, Newport Beach, CA USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY USA
[8] MSKCC, New York, NY USA
[9] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, New York, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187508
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
    Ansell, Stephen M.
    Inwards, David J.
    Rowland, Kendrith M., Jr.
    Flynn, Patrick J.
    Morton, Roscoe F.
    Moore, Dennis F., Jr.
    Kaufmann, Scott H.
    Ghobrial, Irene
    Kurtin, Paul J.
    Maurer, Matthew
    Allmer, Christine
    Witzig, Thomas E.
    CANCER, 2008, 113 (03) : 508 - 514
  • [42] A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia (vol 129, pg 3165, 2017)
    Garzon, R.
    Savona, M.
    Baz, R.
    BLOOD, 2020, 136 (02) : 259 - 259
  • [43] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [44] Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma.
    Gatzemeier, U.
    Blumenschein, G.
    Fosella, F.
    Simantov, R.
    Elting, J.
    Bigwood, D.
    Cihon, F.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 364S - 364S
  • [45] PHASE II TRIAL OF SINGLE-AGENT BEVACIZUMAB FOLLOWED BY BEVACIZUMAB PLUS IRINOTECAN AT TUMOR PROGRESSION IN RECURRENT ANAPLASTIC GLIOMA
    Kreisl, Teri Nguyen
    Butman, John A.
    Hammoud, Dima
    Iwamoto, Fabio M.
    Kim, Lyndon
    Duic, Paul
    Albert, Paul
    Fine, Howard A.
    NEURO-ONCOLOGY, 2009, 11 (05) : 620 - 620
  • [46] Resistance to single-agent chemotherapy and its risk factors in low-risk gestational trophoblastic neoplasms
    Mousavi, Azam Sadat
    Zamani, Ashraf
    Khorasanizadeh, Faezeh
    Gilani, Mitra Modarres
    Zendehdel, Kazem
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2015, 41 (05) : 776 - 783
  • [47] RESISTANCE TO SINGLE-AGENT CHEMOTHERAPY AND ITS RISK FACTORS IN LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASMS
    Mousavi, A.
    Zamani, A.
    Khorasanizadeh, F.
    Gilani, M. Modarres
    Zendehdel, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 665 - 665
  • [48] Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
    Goff, Laura W.
    Benson, Al B., III
    LoRusso, Patricia M.
    Tan, Antoinette R.
    Berlin, Jordan D.
    Denis, Louis J.
    Benner, Rebecca J.
    Yin, Donghua
    Rothenberg, Mace L.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 290 - 298
  • [49] Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
    Seidman, AD
    SEMINARS IN ONCOLOGY, 1999, 26 (03) : 14 - 20
  • [50] Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization
    Mizugaki, Hidenori
    Yamamoto, Noboru
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2051 - U100
12345